Many breast cancer patients develop resistance to standard drug treatments aimed at preventing the growth of cancer cells. Didier Picard‘s group form the Molecular and Cellular Department has identified a molecular regulator involved in these resistance mechanisms. The loss of this regulator leads to the proliferation of cancer cells – even if they are treated – through a signaling pathway that can itself be inhibited by another treatment. The team’s findings make it possible to consider dual therapy for certain patients whose tumors no longer respond to standard treatment.

The article was published in the journal Cancers on Feb. 14th 2022.

Check the UNIGE press release.

The combination of two drugs could overcome resistance to standard treatment.